GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Cyclically Adjusted Revenue per Share

Biomarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted Revenue per Share : MXN240.14 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted revenue per share for the three months ended in Mar. 2025 was MXN77.590. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN240.14 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Biomarin Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biomarin Pharmaceutical was 34.80% per year. The lowest was 11.90% per year. And the median was 14.75% per year.

As of today (2025-05-23), Biomarin Pharmaceutical's current stock price is MXN1480.00. Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN240.14. Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is 6.16.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomarin Pharmaceutical was 44.11. The lowest was 4.95. And the median was 12.86.


Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.45 165.39 185.64 143.32 287.60

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.90 202.82 264.59 287.60 240.14

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


;
;

Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=77.59/134.9266*134.9266
=77.590

Current CPI (Mar. 2025) = 134.9266.

Biomarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 24.467 100.684 32.788
201509 21.908 100.392 29.444
201512 24.320 99.792 32.882
201603 25.226 100.470 33.877
201606 34.138 101.688 45.297
201609 32.269 101.861 42.744
201612 35.923 101.863 47.583
201703 33.115 102.862 43.438
201706 32.907 103.349 42.961
201709 34.632 104.136 44.872
201712 40.098 104.011 52.016
201803 38.516 105.290 49.358
201806 41.421 106.317 52.567
201809 41.283 106.507 52.299
201812 38.799 105.998 49.388
201903 43.606 107.251 54.859
201906 41.601 108.070 51.940
201909 48.961 108.329 60.982
201912 47.738 108.420 59.409
202003 62.897 108.902 77.928
202006 54.852 108.767 68.044
202009 53.283 109.815 65.467
202012 49.460 109.897 60.725
202103 53.887 111.754 65.060
202106 53.858 114.631 63.393
202109 45.873 115.734 53.480
202112 50.269 117.630 57.661
202203 53.062 121.301 59.022
202206 57.290 125.017 61.831
202209 54.769 125.227 59.011
202212 56.332 125.222 60.698
202303 55.311 127.348 58.603
202306 52.336 128.729 54.856
202309 52.968 129.860 55.035
202312 58.195 129.419 60.671
202403 54.040 131.776 55.332
202406 65.058 132.554 66.223
202409 74.482 133.029 75.545
202412 79.203 133.157 80.256
202503 77.590 134.927 77.590

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biomarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1480.00/240.14
=6.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomarin Pharmaceutical was 44.11. The lowest was 4.95. And the median was 12.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Industry
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.